These immune checkpoint inhibitors (ICIs), have revolutionized treatment for advanced NSCLC, particularly in patients lacking driver mutations.2–4 PD-1/PD-L1 inhibitors have also been extended to first-line clinical applications, marking a significant advancement in NSCLC treatment paradigms. Here, CD274 is linked to non-small cell lung carcinoma.